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Myelodysplastic Syndromes • Brief Report
Autologous stem cell transplantation(ASCT) is becoming an acceptedtreatment for patients with high-risk
myelodysplastic syndromes (MDS) in com-
plete remission who lack an HLA-identical
sibling. Although ASCT can be performed in
about 60% of patients with MDS who
obtain a  complete remission after intensive
chemotherapy,1 their long-term outcome is
still unclear because most previous reports
on ASCT in MDS, especially in prospective
studies, have had a relatively short follow-
up.1-10 Therefore, it remains unknown
whether or not autografting can prolong
complete remission duration in at least some
MDS patients. Here we report the outcomes
of 53 high-risk MDS patients autografted in
first complete remission of whom 45 (85%)
were autografted 4 years before the last
analysis of outcome.
Design and Methods
Between March 1992 and March 2001, 53
MDS patients who lacked an HLA identical
sibling and had achieved complete remis-
sion after intensive chemotherapy were
autografted white in first complete remis-
sion. Induction chemotherapy consisted of
intensive anthracycline-AraC chemothera-
py, either alone (MA protocol, 14 patients)
or combined with quinine (MAQ protocol,
11 patients)11 or fludarabine (FAM protocol,
5 patients) or etoposide (9 patients)9 and/or
granulocyte colony-stimulating factor (14
patients).7 Remission status was assessed
according to International Working Group
(IWG) criteria.12 Autografts were performed
as already described.1 Seventeen patients
received autologous bone marrow and 36
autologous peripheral stem cells. The inter-
vals for overall survival, disease-free sur-
vival, relapse rate and risk of transplant-
related mortality were calculated from the
time of the ASCT. Comparisons were made
with the chi squared test. Survival curves
were drawn by the Kaplan Meier method,13
and compared using the log rank test.14
Prognostic factors were assessed using the
Cox model.15 The 53 autografted MDS
patients were prospectively registered. For
the present study, March 2001 was chosen
as the accrual cut-off date in order to pro-
vide sufficient follow-up at the reference
date of 1 June 2003. Toxic deaths were
defined as all deaths occurring within the 3
months after ASCT. Long-term survivors
were defined as patients having survived
more than 4 years after transplantation.
Relapses occurring within the 6 months
after transplantation were defined as early
relapses. To avoid time-associated biases in
this series of patients included over a 9-year
period, long-term survivors were compared
with patients included at least 4 years before
the reference date of 1 June 2003.
Results and Discussion
The median age of the 53 patients was 52
years (range: 18-65). Twenty-nine had acute
myeloid leukemia (AML) secondary to MDS
We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or
acute myeloid leukemia secondary to MDS, autografted in first complete remission.
Five (9.4%) died from the procedure whereas hematological reconstitution occurred in
all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses
occurring within 2 years of the autologous transplant. With a median follow-up of 6.2
years, the median actuarial disease-free survival and overall survival were 8 and 17
months after autograft, respectively. Karyotype was the only prognostic factor for dis-
ease-free and overall survival. The eight survivors (15%), including two patients with
unfavorable or intermediate karyotype, remained in first complete remission 50+ to
119+ months after transplantation and are probably cured.
Key words: myelodysplastic syndrome, intensive chemotherapy, autologous stem cell
transplantation.
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(55%), 15 had refractory anemia with excess blasts
(RAEB) in transformation (RAEB-T) (28%) and 9 had
RAEB (17%). Thirteen patients (24%) had therapy-
related MDS. Overall, 45 patients were successfully
karyotyped. In the 18 non-AML patients who were suc-
cessfully karyotyped, 3 and 15, respectively belonged to
the high-risk and intermediate-2 risk subgroups of the
International Prognostic Scoring System.16 Bone mar-
row and peripheral blood stem cells were harvested 0.5
to 5 months (median 2.3 months) after achieving com-
plete remission and the ASCT was performed 1 to 7
months (median 3.7 months) after achievement of com-
plete remission. The conditioning regimens were a
combination of cyclophosphamide and busulfan in 31
patients, cyclophosphamide, busulfan and etoposide in
14 patients, and cyclophosphamide plus total body irra-
diation in 8 patients. Five patients (9.4%) died from the
procedure. These early deaths, occurring in two bone
marrow recipients and three peripheral blood stem cell
recipients, were characterized by a high proportion of
unfavorable karyotypes: 3/5 versus 4/40 (p=0.021).
Hematologic reconstitution occurred in all remaining 48
patients, without significant differences between the
three conditioning regimens. 
Forty patients (75%) relapsed 3.1 to 37 months
(median 8 months) after transplantation and 8 (15%)
were still in complete remission after 50 to 119 months
(median 80 months). In three of the 40 patients in
relapse, a second prolonged complete remission was
obtained by intensive chemotherapy followed by allo-
geneic stem cell transplantation from an unrelated
donor. All remaining 37 relapsed cases died from pro-
gressive disease. The Kaplan-Meier estimate of overall
survival was 68±7% at 12 months, 40±7% at 24
months, 26±6% at 36 months, and 19±6% at 48
months (Figure 1). The Kaplan-Meier estimate of dis-
ease-free survival was 38±7% at 12 months, 21±6% at
24 months, 15±5% at 36 and 48 months (Figure 1). The
Figure 1. A Survival and B disease free survival of the 53 auto-
grafted MDS patients.
Table 1. Initial characteristics of autografted MDS patients surviv-
ing than or more than 48 months.
Survival
<48 months ≥ 48 months p
(37 patients) (8 patients)
Mean age 48 47 ns
Sex (male/female) 11/26 6/2 0.024
FAB at diagnosis (%) ns
Refractory anemia 7 (19) 0 (0)
Refractory anemia with 17 (46) 4 (50)
excess blasts
Refractory anemia with 13 (35) 3 (37)
excess blasts in transformation
Chronic monomyelocytic leukemia 0 (0) 1 (13)
FAB at the onset of treatment (%) ns
Refractory anemia with 6 (16) 1 (13)
excess blasts 
Refractory anemia with 10 (27) 2 (24)
excess blasts in transformation
Acute myeloma leukemia 21 (57) 5 (63)
Abnormal karyotype (n=38) (%) ns
Normal 13 (43) 5 (72)
-7 (single) 2 (7) 0 (0)
Other single abnormalities 10 (33) 1 (14)
Complex 5 (17) 1 (14)
Risk group, in non-AML  cases according
to the IPSS (at treatment onset)  (n=15) (%) ns
High 10 (83) 2 (67)
Intermediate-2 2 (17) 1 (33)
Hematologic findings
White cell count (mean, 103/mm3) 4.1 6.2 ns
Bone marrow blasts 36.1 40.13 ns
(mean percentage)
Mean interval from diagnosis 7.3 4.7 ns
to treatment (months)
Mean interval from complete remission 3.7 4.2 ns
to ASCT (months)
Yields of harvested cells
CFU-GM (104/kg) 30 48 ns
CD34+ cells (106/kg) 5 4.1 ns
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median disease-free and overall survivals were 8 and 17
months after autograft, respectively. In Cox analysis,
karyotype was the only prognostic factor for outcome
of the autograft (Figure 2), patients with favorable cyto-
genetic findings having a better overall survival than
others (relative risk 0.33, 95% confidence interval 0.14-
0.78, p=0.011). Only cytogenetic abnormalities signifi-
cantly influenced disease-free survival (relative risk
0.36, 95% confidence interval 0.154-0.839; p=0.018).
Fifteen patients who achieved complete hematologic
reconstitution after ASCT relapsed within 6 months of
transplantation. These early relapses were character-
ized by a high proportion of unfavorable karyotypes,
according to the IPSS classification (41.7 vs. 9.5%,
p=0.04).16 All three patients with monosomy 7 relapsed
at 2, 3, and 4 months after ASCT, while five of the
seven patients with complex abnormalities relapsed at
2, 2.6, 4, 4, and 28.1 months.
ASCT was performed 25 to 127 months before the
reference date of analysis (median 74 months), thus
providing a sufficient follow-up to estimate the propor-
tion of long-term survivors in this series of 53 autograft-
ed MDS patients. Among the 48 patients who achieved
hematologic reconstitution after ASCT, 35/40 relapses
(87.5%) occurred in the 2 years after ASCT, while the
remaining five were diagnosed 25, 26, 28, 36, and 37
months after transplantation. The eight patients who
remained alive in first complete remission 50+ to 119+
months (median 89 months) after ASCT were probably
cured. The only difference between the long-term sur-
vivors and the other patients was the significantly high-
er proportion of females among long-term survivors
(6/8 vs. 15/45, p=0.047). Time-dependent factors could
have affected the outcome of MDS patients autografted
at distinct occasions over the 9-year period of the study.
We, therefore, next compared initial characteristics and
outcomes of the eight long-term survivors with those of
the 37 other cases autografted 4 years before the last
outcome analysis (Table 1). Again, the only difference
between long-term survivors and other patients was
the higher proportion of females in the former group.
All but two long-term survivors were females, whereas
only 11 of the 37 patients who survived less than 4
years were females (p=0.029). Of interest, of the seven
successfully karyotyped long-term survivors with per-
sistent complete remission after ASCT, one had a complex
karyotype, one had trisomy 8 and five had a normal
karyotype. 
The main goal of our study was to assess the out-
come of autografted MDS patients after a sufficient fol-
low-up. We thus focused our analysis on 53 patients
prospectively registered between March 1992 and
March 2001 in 11 French centers; the median follow-up
of the study group was 6.2 years. As our analysis
focused on patients actually autografted, overall sur-
vival and disease-free survival were calculated from
ASCT rather than from the time of achieving complete
remission. Karyotype was the only prognostic factor
influencing both overall survival and disease-free sur-
vival. In contrast, there was no significant difference in
the distribution of cytogenetic abnormalities between
long-term survivors and other patients. Interestingly, of
the seven long-term survivors who were successfully
karyotyped, one had a complex karyotype and one had
trisomy 8. These two patients were, respectively, in
first complete remission 50+ and 68+ months after
ASCT, showing for the first time that intensive
chemotherapy followed by ASCT can cure patients
with high-risk MDS and an unfavorable karyotype. 
Prolonged follow-up revealed that the majority of
autografted MDS patients (75%) relapsed and, at 3
years, the Kaplan-Meier estimate of overall survival and
disease-free survival was, respectively, 23±6% and
15±5%. More than 85% of the relapses occurred in the
2 years following transplantation. Cytogenetic abnor-
malities were able to predict these early relapses which
were three times more common in patients with unfa-
vorable karyotypes. By contrast, relapses occurring
after 6 months could not be correlated with FAB classi-
fication, age, sex or karyotype. As shown in Figure 1,
the Kaplan-Meier overall survival curve reached a
plateau at 40 months after ASCT. No relapse occurred
after this period and the median duration of complete
remission of the eight long-term survivors was 89+
months. The unique particular characteristic of these
patients was that most were females (75%). In our pre-
vious experience of 71 MDS patients in complete remis-
sion after intensive chemotherapy without ASCT, who
had over 4 years follow-up, less than 6% of the patients
remained in first complete remission.17 Here, 8/45
(18%) of autografted MDS patients with over 4 years
follow-up experienced prolonged survival in complete
remission.
In conclusion, in this long-term study, 15% of high-
risk MDS patients in first complete remission, including
some with an unfavorable karyotype, experienced pro-
longed disease-free survival and were probably cured
after ASCT. This proportion of long-term survivors
appears to be higher than that obtained with consolida-
tion chemotherapy in our historical series.17 Other treat-
ment approaches might, however, provide better long-
term results. Using intensive chemotherapy with gran-
ulocyte colony-stimulating factor priming followed by
consolidation chemotherapy, Hofman et al. reported
encouraging results with a 16% probability of patients
in complete remission retaining this status after 60
Figure 2. Survival as a function of cytogenetic abnormalities. 
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months.18 Together, these results suggest that intensi-
fied consolidation in patients with MDS may increase
the proportion of long-term, disease-free survivors,
although therapeutic approaches still need to be opti-
mized and/or supplemented in order to decrease the
relapse rate.
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